Announcements - OBI Pharma 台灣浩鼎

2023.May.26

Announcement on behalf of Obigen to change its financial and accounting officer

2023.May.08

The Company’s BOD resolved to amend the plan to disperse shareholding of Obigen (New Shareholding Dispersal Method)

2023.May.08

The Company’s BOD resolved to amend the plan to disperse shareholding of AP Biosciences (New Shareholding Dispersal Method)

2023.May.08

The Company’s Board of Directors resolved to issue 2023 employee stock options and the subscription rules.

2023.May.08

The Company's Board of Directors resolved to convene the 2023 Annual General Shareholders' Meeting (New Approval)

2023.May.08

Announcement of the Consolidated Financial Statements for the first quarter of 2023 were approved by the Board of Directors.

2023.May.05

Announcement on behalf of Amaran of not Distributing Dividends of 2022

2023.May.05

Announcement on behalf of Amaran that the BOD resolved to convene the 2023 Annual General Shareholders' Meeting

2023.Apr.25

OBI is invited to attend the“ 13th Taiwan CEO Week & Taiwan New Economy Day” (Investor meeting on air) held by QIC

2023.Mar.31

OBI has filed the application of Phase I human clinical trial for COVID-19 vaccine, BCVax, to TFDA

News

Latest News

Events

Latest events